Introduction
============

Gout is a common medical problem that mainly affects middle-aged men,[@b1-jpr-12-083] with a peak incidence in the fifth decade of life.[@b2-jpr-12-083] The prevalence of gout increases among postmenopausal women with diuretic-treated hypertension and renal insufficiency.[@b3-jpr-12-083] Risk factors for gout include obesity, alcohol intake, diuretic use, a diet rich in meat, seafood, or high-fructose food or drink intake, and poor kidney function.[@b4-jpr-12-083]--[@b7-jpr-12-083] Furthermore, an increased risk of cardiac disease in patients with gout was observed and this risk is above and beyond that contributed by the traditional risk factors for heart disease.[@b8-jpr-12-083],[@b9-jpr-12-083] Gouty arthritis not only contributes to heart disease but also directly influences the quality of life. Acute gouty arthritis often peaks within 24 hours of onset with a very painful, warm, tender, and swollen joint, and it commonly affects the joints of the lower extremity, particularly the metatarsophalangeal joint.[@b10-jpr-12-083],[@b11-jpr-12-083] According to the 2012 American College of Rheumatology Guidelines for Management of Gout,[@b12-jpr-12-083] nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or oral colchicine are appropriate first-line options for the treatment of acute gout and certain combinations can be used for severe or refractory attacks. They suggest the use of the NSAIDs, such as naproxen, indometacin, and sulindac, for the treatment of acute gout. However, nonselective NSAIDs, which inhibit both cyclooxygenase (COX)-1 and COX-2, are associated with dyspepsia and potential gastrointestinal (GI) perforations, ulcers, and bleeding.[@b13-jpr-12-083],[@b14-jpr-12-083] Etoricoxib, a highly selective COX-2 inhibitor, has demonstrated anti-inflammation, analgesic, and antipyretic properties and reduces the incidence of GI-related adverse events, compared with nonselective NSAIDs.[@b15-jpr-12-083]--[@b18-jpr-12-083] Besides, the cardiovascular safety of COX-2 inhibitor has been revealed.[@b19-jpr-12-083] Indometacin is the most potent inhibitor of nonselective NSAIDs, although a more potent inhibitor of COX-1 than that of COX-2.[@b20-jpr-12-083] We performed a systemic review and meta-analysis to compare the efficacy and safety of etoricoxib and indometacin in the treatment of acute gout.

Methods
=======

Search and study selection
--------------------------

Relevant research articles comparing etoricoxib and indometacin in patients with gouty arthritis were searched by using the following relative terms in PubMed, Embase, Ovid MEDLINE, Web of Science, ScienceDirect, and the Cochrane Library: "gout", "gouty", "gouty arthritis", "uric arthritis", "arthralgia", "Etoricoxib", and "indometacin". The systematic literature search using free-text, medical subject headings (MeSH and Emtree), and Boolean algebras was conducted by two authors to identify citation records without language or publication date restrictions from inception till July 19, 2018 ([Table S1](#SD1-jpr-12-083){ref-type="supplementary-material"}).

The two authors screened the returned citations imported into EndNote (Version X7) for Microsoft Windows. End-Note systematically removed duplications. The authors completed further categorizations and duplications manually. The inclusion criteria in the title and abstract screening phase were as follows: 1) studies involving patients with gout and 2) studies directly comparing etoricoxib and indometacin. The exclusion criteria in the subsequent full-text screening phase were as follows: 1) studies investigating combined therapy, 2) studies not involving a randomized controlled trial (RCT), and 3) articles not reporting a complete study (conference report and relevant documents). The first author (TML) participated in the screening task in case of any disagreement regarding screening categorization between the two authors.

Outcomes assessment
-------------------

This systematic review and meta-analysis conducted outcomes of effects and safety between etoricoxib and indometacin. The outcomes of effects included tenderness, swelling, global assessments, and pain score. There were two parts in global assessments that consisted of patient's assessment and investigator's assessment. The pain score was measured by VAS. The safety outcomes included adverse events that analyzed with subgroup analysis according to systems.

Quality assessment
------------------

This systematic review and meta-analysis assessed the risk of bias by using the appraisal tools of the Risk of Bias Tool of Cochrane. The tool comprises the following items: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of assessment, incomplete outcome data, selective reporting, and other sources of bias. These eight items in the appraisal tool addresses six categories of bias, namely selection bias, performance bias, detection bias, attrition bias, reporting bias, and other bias. Two authors (T-ML and J-EC) individually assessed the included RCTs. The author (Y-NK) participated in the appraisal work in case of any disagreement regarding screening categorization between the two authors.

Data extraction and analysis
----------------------------

Two authors independently performed data extraction. They not only identified relevant data but also double-checked the meaning of the data and converted the data for appropriate pooling analysis. If the included articles reported mean and standard error (SE) without SD, the authors estimated the SD on the basis of the included sample size (SE = SD/√*N*). If the included study reported median values with minimum and maximum only, the authors estimated the mean and SD values from the sample size, median, and range.[@b21-jpr-12-083]

Peto ORs were calculated when dichotomous data involved zero cells. Mean differences (MDs) of the original studies pooled in a random-effects model were used to compare continuous variables measured using the same tool and conditions between etoricoxib and indometacin. *I*^2^ obtained from each meta-analysis was used for estimating the heterogeneity among the included studies. Statistical significance was set at *P*\<0.05 for all analyses. *I*^2^ of the pooled studies was represented using the percentage of total variability across the studies. *I*^2^ values 25, 50, and 75% were considered to indicate low, moderate, and high heterogeneity, respectively.[@b22-jpr-12-083] Data were expressed as risk ratios with 95% CI, and *I*^2^ was calculated and presented in a forest plot and analyzed using the RevMan software (Version 5.3) for Microsoft Windows. Small study bias was detected by using funnel plot with Egger's regression intercept. The systematic review and results of meta-analysis are reported according to the PRISMA guidelines.[@b23-jpr-12-083]

Results
=======

Literature search and selection
-------------------------------

The search returned 313 records, of which 13 citations were from PubMed, 99 citations were from Embase, 123 citations were from Ovid MEDLINE, 33 citations were from ScienceDirect, 32 citations were from Web of Science, and 13 citations were from the Cochrane Library. Of these, 85 citations were duplicated. According to the exclusion criteria, 211 citations were excluded after title and abstract screening. In the full-text screening phase, 13 non-RCTs and conference reports were excluded. The literature identification and study selection process are presented in [Figure 1](#f1-jpr-12-083){ref-type="fig"}.

Characteristics of included studies
-----------------------------------

The four RCTs included in this synthesis randomized 609 patients, with 14 patients lost to follow-up.[@b24-jpr-12-083]--[@b27-jpr-12-083] [Table 1](#t1-jpr-12-083){ref-type="table"} lists the study characteristics including trial location, inclusion years, sample size, patients' age, sex, disease classification, and index joint, and loss to follow-up. These studies spanned approximately 15 years from 2002 to 2016 and involved Africa, America, and Asia. Most of the included patients were men. [Figure 2](#f2-jpr-12-083){ref-type="fig"} presents the individual quality of the included studies. In summary, the quality of the studies was acceptable, except for the reporting bias item. The four RCTs had a high risk of bias (25%) in terms of allocation generation, allocation concealment, blinding, and incomplete outcome data. However, the risk of reporting bias was high ([Figure S1](#SD1-jpr-12-083){ref-type="supplementary-material"}).

Effect outcomes
---------------

The effects of etoricoxib and indometacin on gouty arthritis are presented in [Table 2](#t2-jpr-12-083){ref-type="table"}. In two included studies with 363 patients with acute gouty arthritis,[@b24-jpr-12-083],[@b25-jpr-12-083] the presented evidence revealed no significant differences in pain score change in days 2--5 and days 2--8 between etoricoxib and indometacin and the MDs were --0.05 (95% CI, --0.21 to 0.10; *P*\>0.05) and --0.05 (95% CI, −0.20 to 0.10; *P*\>0.05) ([Figure S2](#SD1-jpr-12-083){ref-type="supplementary-material"}). These two analyses were conducted with low heterogeneity (*I*^2^=0%; *P*\>0.05). Three trials reported the effect of the two medications on tenderness.[@b24-jpr-12-083]--[@b26-jpr-12-083] The pooled data of 510 patients revealed no significant difference in tenderness between etoricoxib and indometacin (MD =−0.06; 95% CI, −0.18 to 0.05; *P*\>0.05) ([Figure S3](#SD1-jpr-12-083){ref-type="supplementary-material"}). Three of the four included RCTs reported information on swelling.[@b24-jpr-12-083]--[@b26-jpr-12-083] The meta-analysis based on data from 510 patients showed no significant difference between etoricoxib and indometacin (MD =−0.04; 95% CI, −0.17 to 0.09; *P*\>0.05) ([Figure S4](#SD1-jpr-12-083){ref-type="supplementary-material"}). Moreover, the pooled data of three RCTs with 505 patients revealed no significant difference in the patient's global assessment between the two drugs (MD =−0.09; 95% CI, −0.25 to 0.06; *P*\>0.05) ([Figure S5](#SD1-jpr-12-083){ref-type="supplementary-material"})[@b24-jpr-12-083]--[@b26-jpr-12-083] and the meta-analysis of three RCTs with 507 patients also indicated no statistical difference in the investigator's global assessment between the drugs (MD =−0.11; 95% CI, −0.22 to 0.01; *P*\<0.05) ([Figure S6](#SD1-jpr-12-083){ref-type="supplementary-material"}).[@b24-jpr-12-083]--[@b26-jpr-12-083] Low heterogeneity (*I*^2^=0%; *P*\>0.05) was found in all the meta-analyses of effect outcomes.

Safety outcomes
---------------

Four RCTs reported adverse events.[@b24-jpr-12-083]--[@b27-jpr-12-083] The pooled data of 608 patients revealed that fewer overall adverse events occurred in the etoricoxib group (n=105, 33.5%) than in the indometacin group (n=130, 44.1%) with significance, and the risk ratio was 0.77 (95% CI, 0.62--0.94; *P*\<0.05) ([Figure 2](#f2-jpr-12-083){ref-type="fig"}). The heterogeneity of this pooled analysis was also low (*I*^2^=9%; *P*\>0.05). Sensitivity analysis showed that trend of the result was not changed when any included RCT was removed from the meta-analysis ([Figure S7](#SD1-jpr-12-083){ref-type="supplementary-material"}). The Egger's test (*t*=1.523; 95% CI, −6.211 to 2.963; *P*=0.267) did not detect small study bias in this result ([Figure S8](#SD1-jpr-12-083){ref-type="supplementary-material"}).

According to the available data, this systematic review identified adverse events of the digestive system, nervous system, and general symptoms. Data on adverse events of the respiratory system, cardiovascular system, and severe adverse events were insufficient to conduct a meta-analysis. The adverse events of the digestive system include abdominal distention, gastrectasia, diarrhea, stomach upset, stomachache, digestive tract upset, nausea, vomiting, and dry mouth. The nervous system adverse events were somnolence and hand numbness. The general symptoms were dizziness, vertigo, chills, fever, pedal edema, and headache. The pooled data of four RCTs with 608 patients revealed that the etoricoxib group (n=19, 6.1%) had fewer digestive system adverse events than the indometacin group (n=45, 15.3%), with the Peto OR being 0.37 (95% CI, 0.22--0.62; *P*\<0.05) ([Figure 3](#f3-jpr-12-083){ref-type="fig"}, 2.2.1).[@b24-jpr-12-083]--[@b27-jpr-12-083] Three of the included four RCTs reported information on nervous system adverse events.[@b24-jpr-12-083],[@b26-jpr-12-083],[@b27-jpr-12-083] The evidence revealed that the etoricoxib group (n=1, 0.5%) had fewer nervous system adverse events than the indometacin group (n=9, 4.3%), with the Peto OR being 0.19 (95% CI, 0.06--0.68; *P*\<0.05) ([Figure 3](#f3-jpr-12-083){ref-type="fig"}, 2.2.2).[@b24-jpr-12-083],[@b26-jpr-12-083],[@b27-jpr-12-083] However, the meta-analysis of the three RCTs with 419 patients indicated no difference in general symptoms between the two groups, with the Peto OR being 0.55 (95% CI, 0.29--1.05; *P*\>0.05) ([Figure 3](#f3-jpr-12-083){ref-type="fig"}, 2.2.3).[@b24-jpr-12-083]--[@b26-jpr-12-083]

Discussion
==========

Contribution of etoricoxib to gout
----------------------------------

Acute gouty arthritis is the most common form of inflammatory arthritis. Prostaglandins play a major role in the process of inflammatory response. They are derived from arachidonic acid through the action of COX isoenzymes. COX-1 is constitutively expressed in most cells and is responsible for homeostatic functions, which include epithelial cytoprotection, platelet aggregation, and renal blood flow regulation.[@b28-jpr-12-083] COX-2, induced by inflammatory stimuli, is the dominant source of prostaglandins in inflammation.[@b28-jpr-12-083],[@b29-jpr-12-083] Human data indicate that COX-1-derived prostanoids drive the initial phase of inflammation, whereas COX-2 upregulation occurs several hours later.[@b30-jpr-12-083]--[@b32-jpr-12-083] Both COX-1 and COX-2 are involved in the process of acute inflammation; moreover, our study revealed comparable effects of etoricoxib and indometacin on gouty arthritis.

In the analyzed studies, digestive tract upset was the most common complication in patients under treatment with either etoricoxib or indometacin. NSAID-induced injuries to the GI tract ranging from petechia to ulcers were not rarely observed. They disrupted the mucosa of the GI tract, causing bleeding, perforation, or obstruction.[@b33-jpr-12-083] NSAID-induced ulcerative lesions of the stomach predominantly result from systemic effects associated with the mucosa and topical injury to the mucosa. In systemic effects, COX inhibition was reported to lead to platelet inhibition and prostanoid depletion.[@b33-jpr-12-083] When platelets are inhibited, gastric ulcer healing may be influenced through altering the ability of releasing growth factors such as EGF and vascular endothelial growth factor.[@b34-jpr-12-083],[@b35-jpr-12-083] Hence, inhibition with selective COX-2 inhibitors may be safer in the GI tract and in platelets.[@b36-jpr-12-083] In the RCTs analyzed in this systematic review,[@b24-jpr-12-083]--[@b27-jpr-12-083] the incidence of the adverse events of the digestive system was significantly lower in patients taking etoricoxib than in those taking indometacin, a finding that is consistent with the aforementioned results. Additionally, recent results have revealed that both COX isozymes may be a source of cytoprotective prostanoids for inhibiting COX-1 and upregulating COX-2 expression, despite the possible existence of subsequent deleterious effects such as gastric hypermotility.[@b37-jpr-12-083] Hence, inhibition of both COX-1 and COX-2 may increase the risk of gastric lesion formation.[@b37-jpr-12-083]

PGE2 and PGI2 are the main protective prostaglandins. Inhibiting them by using NSAIDs may decrease the stimulation of the synthesis and secretion of mucus and bicarbonate and reduce mucosal blood flow and epithelial proliferation, resulting in tropical injury of the stomach mucosa, thus making it susceptible to endogenous and exogenous factors such as acid and *Helicobacter pylori* infection.[@b33-jpr-12-083] In addition, NSAIDs that are weak acids may cause topical damage of the epithelium at the site of the GI mucosa, according to the hypothesis that NSAIDs would compromise the extracellular zwitterionic phospholipid hydrophobic surface barrier of the stomach to luminal acid.[@b38-jpr-12-083]

The perfusion of the luminal surface of the stomach is essential for mucosal integrity.[@b33-jpr-12-083] When focal gastric mucosal blood flow decreases, the mucosa becomes more susceptible and NSAID-induced injuries such as hemorrhagic foci and ulceration may occur at the focal ischemic patch.[@b39-jpr-12-083] PGE2 and PGI2 are vasodilators, and inhibiting their synthesis is likely to cause focal ischemia; however, selective COX-2 NSAIDs do not reduce gastric mucosa blood flow.[@b40-jpr-12-083],[@b41-jpr-12-083] Inhibiting TXA2 production through platelet COX-1 inhibition increases the bleeding tendency when an active GI bleeding site is present.[@b42-jpr-12-083] Most (86%) of the NSAIDs' GI effects are in the upper GI tract.[@b43-jpr-12-083] One effective strategy for managing NSAID-GI bleeding is proton pump inhibitors (PPIs). The PPI strategy for NSAID-GI risk reduction is that this approach covers the proportion of events occurring only in the upper GI tract[@b44-jpr-12-083] and it can significantly reduce the risk of upper GI bleeding.[@b45-jpr-12-083] Moreover, leukocytes may be one of the factors in the pathogenesis of NSAID-induced gastric ulceration. NSAIDs such as indometacin are potent promoters of leukocytes, particularly neutrophils, and adhere to the vascular endothelium within GI microcirculation, leading to mucosal injury.[@b46-jpr-12-083],[@b47-jpr-12-083]

In the small intestine, topical damage engendered by NSAIDs plays a key role in the pathogenesis of intestinal injury; it could be concluded that the intensity of the intraluminal mucosal injury is related to the duration for which the epithelium has been exposed to these drugs and enterohepatic circulation contributes extensively to this process.[@b33-jpr-12-083]

Adverse events in renal function are also noteworthy. Both COX-1 and COX-2 are expressed in the kidneys. Inhibition of the renal prostaglandin E2 can result in the sodium retention and edema and exacerbation of hypertension. Inhibition of prostacyclin expression can reduce renal blood flow and glomerular filtration rate.[@b48-jpr-12-083]

Strengths, limitations, and implications for future research
------------------------------------------------------------

The present study has more advantages than published systematic reviews and meta-analyses.[@b49-jpr-12-083],[@b50-jpr-12-083] The advantages of this systematic review and meta-analysis are as follows: 1) a more specific pharmacological comparison was conducted between etoricoxib and indometacin, which are the most potent inhibitors of nonselective NSAIDs; 2) a new RCT was involved; 3) a more meaningful subgroup analysis on complications was conducted; and 4) a modified statistical method of Peto ORs was used when dichotomous data indicated zero cells. Therefore, the present findings may be more reliable than those of previous meta-analyses.

Despite its advantages, the present meta-analysis has some limitations. Although our meta-analysis exhibited low heterogeneity, some limitations may be reflected in the characteristics of the included RCTs. First, the population in the four included RCTs was predominantly male. Therefore, the results of the present meta-analysis may not satisfactorily represent the female population. Second, disease classification and index joint may influence drug effects. However, the present meta-analysis cannot separately access the data according to disease classification and index joint. The present meta-analysis could provide only an overview of the comparison of the effects and safety of etoricoxib and indometacin. Future research must determine the effects and safety of the two drugs by considering different sexes, disease classification, and index joint. A well-designed RCT or meta-analysis of individual patient data may be warranted in the future. Third, PPI is recommended to prevent NSAID-GI bleeding, but the RCTs we included in this systematic review and meta-analysis did not reported any PPI usage. Thus, the combined effect of PPI and the two drugs should be investigated in further trials. Moreover, the present meta-analysis cannot assess publication bias. Because all of the outcomes pooled from only four RCTs, this meta-analysis cannot constructed meaningful funnel plots for publication bias assessment.[@b51-jpr-12-083]

Conclusion
==========

From our meta-analysis, we found that etoricoxib has more favorable trend than indometacin in providing pain relief in acute gouty arthritis. Moreover, etoricoxib has a significantly lower risk of adverse events than indometacin, particularly for digestive system adverse effects. The effects of etoricoxib and indometacin among all the medications including interleukin-1 inhibitors, colchicine, and glucocorticoids should be investigated in future studies.
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![Flowchart of literature identification and study selection for a systematic review and meta-analysis according to PRISMA guidelines.\
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###### 

Characteristics of included RCTs

  Item                                        Li et al (2013)[@b24-jpr-12-083]   Rubin et al (2004)[@b25-jpr-12-083]   Schumacher et al (2002)[@b26-jpr-12-083]   Xu et al (2016)[@b27-jpr-12-083]                                                              
  ------------------------------------------- ---------------------------------- ------------------------------------- ------------------------------------------ ---------------------------------- ---------------------- ------------ ---------------------- -------------
                                                                                                                                                                                                                                                                
  Location                                    China                              China                                 America, Africa, Philippines               America, Africa, Philippines       NR                     NR           China                  China
  Inclusion period                            Jan 2005 to May 2005                                                     NR                                         NR                                 Jun 2000 to Dec 2000                Apr 2015 to Aug 2015   
  Sample size                                 90                                 89                                    103                                        86                                 75                     75           46                     45
  Age (years) (mean ± SD)                     52±15                              53±14                                 51.1±13                                    52.2±12                            48.5±13.29             49.5±13.71   44.43±15.08            43.81±12.29
  Sex (male)                                  85 (96%)                           81 (91%)                              98 (95%)                                   78(91%)                            73 (97%)               69 (92%)     44 (96%)               35 (78%)
  Disease classification                                                                                                                                                                                                                                        
   Monoarticular                              75 (83%)                           73 (82%)                              81 (79%)                                   63 (73%)                           46 (61%)               53 (71%)     NR                     NR
   Polyarticular                              14 (16%)                           16 (18%)                              22 (21%)                                   23 (27%)                           29 (39%)               22 (30%)     NR                     NR
  Index joint                                                                                                                                                                                                                                                   
   Metatarsophalangeal                        46 (51%)                           53 (60%)                              27 (26%)                                   29 (34%)                           25 (33%)               30 (40%)     16 (35%)               15 (33%)
   Foot, ankle, or knee                       37 (41%)                           27 (30%)                              41 (40%)                                   32 (%)                             27 (36%)               32 (43%)     27 (59%)               21 (47%)
   Great toe proximal interphalangeal joint   0 (0%)                             0 (0%)                                10 (10%)                                   10 (12%)                           0 (0%)                 0 (0%)       0 (0%)                 0 (0%)
   Elbow, wrist, or hand                      4 (4%)                             5 (6%)                                0 (%)                                      0 (0%)                             0 (0%)                 0 (0%)       1 (2%)                 0 (0%)
   Other joints                               2 (2%)                             4 (4%)                                25 (24%)                                   15 (17%)                           23 (31%)               13 (17%)     0 (0%)                 0 (0%)
  Treatment                                                                                                                                                                                                                                                     
   Dosage (mg)                                120                                75                                    120                                        50                                 120                    50           120                    50
   Duration (days)                            5                                  5                                     8                                          8                                  8                      8            4                      4
  Loss to follow-up                           1 (1%)                             0 (0%)                                0 (0%)                                     0 (0%)                             0 (0%)                 0 (0%)       4 (7%)                 9 (20%)

**Abbreviations:** NR, not reported; RCTs, randomized controlled trials.

###### 

Effect outcome summary

  Outcomes                     Studies (n)   Etoricoxib (n)   Indometacin (n)   MD      95% CI        *I*^2^ (%)
  ---------------------------- ------------- ---------------- ----------------- ------- ------------- ------------
                                                                                                      
  Pain score change                                                                                   
   Days 2--5                   2             191              172               −0.05   −0.21--0.10   0
   Days 2--8                   2             191              172               −0.05   −0.20--0.10   0
  Tenderness                   3             265              245               −0.06   −0.18--0.05   0
  Swelling                     3             265              245               −0.04   −0.17--0.09   0
  Global assessment                                                                                   
   Patient's assessment        3             262              243               −0.09   −0.25--0.06   0
   Investigator's assessment   3             263              244               −0.11   −0.22--0.01   0

**Abbreviation:** MD, mean difference.

[^1]: These authors contributed equally to this work
